

- Neuritic plaque, in AD, 2599, 2600f
- Neuritis  
 optic. *See* Optic neuritis  
 oral, 237
- Neuroanthocytosis, 2622
- Neuroblastoma  
 genetic considerations in, 101e-2t, 101e-3  
 paraneoplastic syndromes in, 618  
 tumor markers in, 473t
- Neurocutaneous melanosis, 441e-37f
- Neurocysticercosis  
 brain abscess in, 900  
 clinical features of, 902-903, 1430-1431, 1431f  
 diagnosis of, 903, 1431, 1431t  
 etiology of, 902  
 treatment of, 903, 1432
- Neurodegeneration with brain iron accumulation (NBIA), 2625-2626
- Neuroendocrine tumors (NETs)  
 appendiceal, 561t, 563, 567  
 bronchial, 560t, 563-564, 2339  
 carcinoma of unknown primary and, 120e-2t, 120e-4  
 classification of, 560, 561t  
 gastrointestinal. *See* Gastrointestinal neuroendocrine tumors (GI-NETS)  
 general characteristics of, 557, 558t  
 genetic syndromes associated with, 562, 562t  
 in MEN 1, 2336t, 2339  
 ovarian, 564  
 pancreatic. *See* Pancreatic neuroendocrine tumors (pNETs)  
 pathology of, 557-558, 558t  
 prognostic factors in, 561t  
 testicular, 564  
 thymic, 564, 2339  
 well-differentiated, 560
- Neuroepithelioma, peripheral, 119e-4
- Neurofibrillary tangles, 76
- Neurofibroma, 364
- Neurofibromatosis type 1 (NF1)  
 clinical features of, **2343**  
 hypertension, 1620t  
 pheochromocytoma, 2331-2332, 2331f  
 primary CNS tumors, 599t, 603-604  
 genetic considerations in, **603, 2343**  
 chromosomal location, 101e-6t, 562t, 2337t  
*NF1* gene mutations, 101e-6t, 599t, 1620t, 2331  
 imaging in, 441e-35f, 2331f  
 NETs in, 562, 562t  
 pheochromocytoma in, 2330-2331, 2331f  
 skin manifestations of, **2331**  
 axillary freckling, 2331f  
 hyperpigmentation, 359, 360t  
 Lisch nodules of the iris, 2331f  
 neurofibromas, 76e-16f, 604, 2331f  
 papulonodular lesions, 364  
 soft tissue sarcomas in, 119e-1
- Neurofibromatosis type 2 (NF2)  
 clinical features of, 220, 599t, 604, 2343  
 CNS tumors in, 599t, 604  
 genetic considerations in, 101e-6t, 599t, 604  
 imaging in, 441e-36f
- Neurofibromin, 603, 2343
- Neurogenic ptosis, 208
- Neurogenic shock, 1748t, **1750**
- Neurohypophysis. *See* Posterior pituitary
- Neuroimaging, **440e-1**. *See also specific disorders*  
 atlas of, 441e-1-43f  
 CT, **440e-1**. *See also* Computed tomography (CT), in neurologic disease  
 complications of, 440e-2, 440e-4, 440e-4t  
 guidelines for, 440e-1t  
 indications for, 440e-1t, 440e-2  
 technique, 440e-1, 440e-2f  
 interventional neuroradiology, 440e-11  
 magnetic resonance angiography, 440e-6-8  
 MRI, **440e-4**. *See also* Magnetic resonance imaging (MRI), in neurologic disease  
 arterial spin labeling, 440e-8  
 complications of, 440e-5-6  
 contrast agents, 440e-5  
 diffusion tensor, 440e-8, 440e-9f  
 diffusion-weighted, 440e-3f, 440e-5f, 440e-8  
 echo-planar, 440e-8  
 FLAIR. *See* Fluid-attenuated inversion recovery (FLAIR) MRI  
 functional, 90f, 440e-8  
 guidelines for, 440e-1t  
 magnetic resonance neurography, 440e-8  
 perfusion, 440e-8  
 technique, 440e-4-5, 440e-4t  
 myelography, 440e-9-10  
 positron emission tomography, 440e-8-9. *See also* Positron emission tomography (PET), in neurologic disease  
 in spine interventions, 440e-10
- Neurokinin (NK<sub>1</sub>), 258
- Neurokinin (NK<sub>1</sub>) receptor antagonists, 103e-25
- Neuroleptic malignant syndrome (NMS), 2624, 2643
- Neuroleptics. *See also* Antipsychotics  
 adverse effects of, 65, 326, 2624  
 for delirium, 64, 64t  
 for Tourette's syndrome, 2623
- Neurologic disease. *See also specific diseases*  
 approach to the patient. *See* Neurologic examination/consultation  
 in Behçet's syndrome, 2194  
 in critically ill patient. *See* Critically ill patient, neurologic disorders  
 depression in, 2714  
 electrodiagnostic studies of. *See specific techniques and* Electrodiagnostic studies  
 fatigue in, 152  
 gene therapy for, 91e-2f  
 genome-wide association studies of, 444e-1  
 global burden of, 2535, 2535t  
 in HIV infection. *See* HIV infection, neurologic disease in  
 in hypothermia, 478e-2t  
 hypoventilation in, 1721, 1721f  
 imaging studies. *See* Neuroimaging  
 insomnia in, 191  
 involuntary weight loss in, 275  
 as late consequence of cancer/cancer therapy, 622  
 localization of, 2535, 2540t  
 mechanisms of, **444e-1**  
 cell death, 444e-8-9, 444e-8f  
 channelopathies, 444e-2, 444e-2t  
 genetic, 444e-1-2, 444e-2t  
 gene transcription disorders, 444e-4  
 microbiota, 444e-6-7  
 myelin disorders, 444e-4-5, 444e-4f  
 neurotransmitter/neurotransmitter receptor disorders, 444e-2-4, 444e-3t  
 neurotrophic factors, 444e-7, 444e-7t  
 paraneoplastic. *See* Paraneoplastic syndromes, neurologic  
 prions, 444e-10-12, 444e-12t  
 protein aggregation, 444e-9-10  
 signaling pathway defects, 444e-4  
 in megaloblastic anemia, 643  
 nutritional deficiencies and, 463t  
 in pregnancy, 49  
 prevalence of, 2535  
 research in, 444e-12-13  
 in sarcoidosis, 2206t, 2208  
 in SLE, 2128-2129, 2129t  
 stem cell therapy in, 90e-3, 444e-7-8  
 in syphilis. *See* Neurosyphilis  
 testicular dysfunction in, 2366  
 in Wilson's disease, 2519
- Neurologic examination/consultation, **463e-1, 2535**  
 after cardiac bypass, 463e-2-3, 463e-2f  
 after solid organ transplantation, 463e-3  
 in back pain, 113, 114t  
 in coma, 1773-1775, 1774f  
 coordination examination, 2539  
 cranial nerve examination, 2537-2538  
 in delirium, 168  
 detailed, 439e-1v  
 in dizziness and vertigo, 149  
 in electrolyte disturbances, 463e-3-4  
 gait examination, **2539**  
 in headache, 107  
 in hyperperfusion states, 463e-1-2, 463e-1t, 463e-2f  
 imaging studies. *See* Neuroimaging  
 localization of findings in nervous system, 2539-2540, 2540t  
 mental status examination, 2537  
 motor examination, 2538  
 in neck pain, 121t  
 neurologic history in, 2535-2536  
 neurologic method in, 2535  
 in olfactory/taste dysfunction, 216  
 overview of, 438e-1v, 439e-1v, 2536-2537  
 in peripheral nervous system dysfunction, 463e-4-5, 463e-5f  
 reflex examination, 2538-2539  
 screening, 438e-1v  
 sensory examination, **2539**
- Neurologic-myopathic syndromes, in lung cancer, 511
- Neuroma, 364t, 2340. *See also* Vestibular schwannoma (acoustic neuroma)
- Neuromuscular blocking agents, 462e-20t, 1732-1733, 1741, 1784
- Neuromuscular jitter, 442e-6
- Neuromuscular junction disorders, **2701**  
 autonomic dysfunction in, 2642  
 botulism. *See* Botulism  
 clinical features of, 2540t  
 congenital myasthenic syndrome, 2702, 2703t  
 in critically ill patient, 1784  
 Lambert-Eaton myasthenic syndrome. *See* Lambert-Eaton myasthenic syndrome (LEMS)  
 myasthenia gravis. *See* Myasthenia gravis  
 progressive external ophthalmoplegia. *See* Progressive external ophthalmoplegia  
 weakness in, 155, 157
- Neuromyelitis optica (NMO), 2656, 2673, 2673t
- Neuromyotonia, 444e-2t, 462e-3, 619
- Neuronal nicotinic acetylcholine receptor, 372e-25t
- Neuron-specific enolase (NSE)  
 as brain damage indicator, 1781  
 in carcinoma of unknown primary, 120e-2t  
 in nonfunctional pNETs, 571  
 as tumor marker, 473t
- Neuro-ophthalmology, 41e-1v
- Neuropathic joint (Charcot's joint) disease, 1136, 2243-2244, 2243f, 2243t
- Neuropathic (lower motor neuron) weakness, 154, 154t, 157
- Neuropathy. *See also* Peripheral neuropathy;  
 Polyneuropathy  
 acute quadriplegic, 462e-20  
 anti-Hu paraneoplastic, 2700  
 diabetic. *See* Diabetic neuropathy  
 entrapment, 49, 463e-4  
 femoral, 2692  
 gait disorders in, 163-164  
 in HIV infection. *See* HIV infection, neurologic disease in  
 immune-mediated, 2696t  
 acute motor axonal neuropathy, 2695, 2695t  
 acute motor sensory axonal neuropathy, 2695, 2695t  
 anti-Hu paraneoplastic neuropathy, 2700  
 chronic inflammatory demyelinating polyneuropathy, 2698-2699  
 Guillain-Barré syndrome. *See* Guillain-Barré syndrome (GBS)  
 Miller-Fisher syndrome, 2695, 2695t  
 in monoclonal gammopathy of undetermined significance, 2700  
 multifocal motor neuropathy, 2699  
 in multiple myeloma, 2699-2700  
 vasculitic neuropathy, 2700  
 lateral femoral cutaneous, 49, 463e-5, 463e-5f, 2692  
 median, 2683, 2691  
 multifocal motor, 2699  
 obstetric, 463e-5  
 optic. *See* Optic neuropathy